Chang Lu

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.

Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs . immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.

Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs . immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.

Journal: Chinese medical journal

Published: September 29, 2025

Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis

Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: September 29, 2025

Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?-A Case Report.

Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?-A Case Report.

Journal: Thoracic cancer

Published: September 26, 2025

Causal relationship between oral/gut microbiota and lung cancer: a two-sample Mendelian randomization study.

Causal relationship between oral/gut microbiota and lung cancer: a two-sample Mendelian randomization study.

Journal: Discover oncology

Published: July 26, 2025

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.

Journal: Biomarker research

Published: May 24, 2025

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.

Journal: Nature reviews. Clinical oncology

Published: May 05, 2025

An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al.

An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al.

Journal: Translational oncology

Published: May 01, 2025

C1orf116 inhibits acquired resistance to EGFR inhibitors in EGFR mutant lung adenocarcinoma by suppressing the ATM/ATR pathways.

C1orf116 inhibits acquired resistance to EGFR inhibitors in EGFR mutant lung adenocarcinoma by suppressing the ATM/ATR pathways.

Journal: Translational lung cancer research

Published: March 06, 2025

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Journal: Translational lung cancer research

Published: October 17, 2024

PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.

PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.

Journal: Clinical lung cancer

Published: October 09, 2024

A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR-Mutant Non-Small Cell Lung Cancer.

A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR-Mutant Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: October 07, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026